Evidence map›Paper›PMID 39772591›Full record

ArticleHypertension (Dallas, Tex. : 1979)2025

NPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress.

Xiaoyu Ma, Joute Chawngvawr Malsawmzuali, Dante G Moroni, Xiao Ma, Ye Zheng, Shuchong Pan, Ying Wang, S Jeson Sangaralingham, John C Burnett

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoyu MaCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0002-9347-3565
Joute Chawngvawr MalsawmzualiCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.
Dante G MoroniCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0002-0963-0346
Xiao MaCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.
Ye ZhengCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.
Shuchong PanCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.
Ying WangCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0002-7852-386X
S Jeson SangaralinghamCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0002-3967-8703
John C BurnettCardiorenal Research Laboratory, Department of Cardiovascular Medicine (Xiaoyu Ma, J.C.M., D.G.M., Xiao Ma, Y.Z., S.P., Y.W., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.

Funding

Novel Therapeutics for Cardiovascular DiseaseR01HL158548 · NHLBI · MAYO CLINIC ROCHESTER · PI MALANY, SIOBHAN, SANGARALINGHAM, SASANTHA JESON · 2022 to 2025
$2.8M
Novel Peptide Therapeutics for HypertensionR01HL136340 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2018 to 2021
$2.5M
Novel Peptide Therapeutics for Cardiorenal Protection in Heart FailureR01HL134668 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL134668NHLBI NIH HHS R01 HL136340NHLBI NIH HHS R01 HL158548
6 · The paper itself

Abstract

backgroundCardiomyocyte oxidative stress significantly contributes to the progression of hypertension-induced heart failure, highlighting the need for targeted therapies. We developed a novel peptide, NPA7, that coactivates the GC-A (guanylyl cyclase A)/cGMP and MasR (Mas receptor)/cAMP pathway. This study aimed to test NPA7's ability to inhibit oxidative stress by modulating the p62 (Sequestosome 1)-KEAP1 (Kelch-like ECH-associated protein 1)-NRF2 (nuclear factor erythroid 2-related factor 2) pathway in human cardiomyocytes (HCMs) and a rat model of hypertension.

methodsOxidative stress was induced in HCMs using H

resultsNPA7 reduced H

conclusionsNPA7 exhibits antioxidant properties in HCMs and spontaneously hypertensive rat hearts by targeting GC-A and MasR through the p62-KEAP1-NRF2 pathway, supporting a novel therapeutic approach against cardiovascular disease-related oxidative stress.

Indexed as

HypertensionMyocytes, CardiacOxidative StressAnimalsDisease Models, AnimalHumansHydrogen PeroxideKelch-Like ECH-Associated Protein 1MaleNADPH OxidasesNF-E2-Related Factor 2RatsRats, Inbred SHRRats, Inbred WKYReactive Oxygen SpeciesSignal TransductionHydrogen PeroxideKelch-Like ECH-Associated Protein 1NADPH OxidasesNF-E2-Related Factor 2Reactive Oxygen Speciesantioxidantscyclic AMPcyclic GMPhypertensionoxidative stress

Identifiers

PMID39772591
PMCPMC11839381

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.